Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer (Q64083922)

2

0 references

Liping Liu

3

0 references

Jingyu Liu

4

0 references

Yu Tang

5

0 references

Mengjia Xiao

6

0 references

Yikai Wang

7

0 references

Qiongzhi He

8

0 references

Zhe-Yu Hu

Breast cancer statistics, 2013.

9

0 references

language of work or name

English

0 references

publication date

May 2019

0 references

published in

Translational Oncology

0 references

volume

12

0 references

issue

5

0 references

page(s)

764-774

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Functional miRNAs in breast cancer drug resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Biomarkers and multiple drug resistance in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

The implications of clonal genome evolution for cancer medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Estrogen Receptors as Therapeutic Targets in Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Comprehensive molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Mutation of GATA3 in human breast tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

The PIK3CA gene is mutated with high frequency in human breast cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

The phosphoinositide 3-kinase pathway and therapy resistance in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Direct detection of early-stage cancers using circulating tumor DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G2 /M Arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Precision medicine for metastatic breast cancer--limitations and solutions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

PIK3CA mutation associates with improved outcome in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANON.2019.02.014

Estrogen receptors as therapeutic targets in breast cancer

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30893632

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30893632

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30893632